FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean‐Baptiste Bachet, E. François et al.|New England Journal of Medicine|2018Cited by 2.8k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trialThierry Conroy, Jean‐Baptiste Bachet, Jean-François Bosset et al.|The Lancet Oncology|2021Cited by 1.3k
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean François Seitz, Florence Castan et al.|JAMA Oncology|2022Cited by 322
<i>BRAF</i> mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastasesStéphane Benoist, Nathan Moreno-Lopez, Luca Viganò et al.|British journal of surgery|2019Cited by 42